Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
The closing price of Protalix BioTherapeutics Inc (AMEX: PLX) was $1.58 for the day, up 1.94% from the previous closing price of $1.55. In other words, the price has increased by $1.94 from its previous closing price. On the day, 0.6 million shares were traded.
Ratios:
Our analysis of PLX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.69 and its Current Ratio is at 2.49. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.08.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on June 08, 2020, Reiterated its Buy rating but revised its target price to $11 from $3 previously.
On April 17, 2017, Rodman & Renshaw reiterated its Buy rating and also lowered its target price recommendation from $4 to $5.
On April 04, 2016, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $3.50.Rodman & Renshaw initiated its Buy rating on April 04, 2016, with a $3.50 target price.
Valuation Measures:
As of this moment, Protalix’s Price-to-Earnings (P/E) ratio for their current fiscal year is 37.62, and their Forward P/E ratio for the next fiscal year is 2.45. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.10 while its Price-to-Book (P/B) ratio in mrq is 2.73.
Stock Price History:
Over the past 52 weeks, PLX has reached a high of $3.10, while it has fallen to a 52-week low of $0.82. The 50-Day Moving Average of the stock is -32.06%, while the 200-Day Moving Average is calculated to be -13.59%.
Shares Statistics:
A total of 78.13M shares are outstanding, with a floating share count of 73.81M. Insiders hold about 7.28% of the company’s shares, while institutions hold 11.19% stake in the company.
Earnings Estimates
The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 2 analysts. It ranges from a high estimate of $15.41M to a low estimate of $11.56M. As of the current estimate, Protalix BioTherapeutics Inc’s year-ago sales were $13.3MFor the next quarter, 2 analysts are estimating revenue of $17.72M. There is a high estimate of $18.17M for the next quarter, whereas the lowest estimate is $17.28M.
A total of 2 analysts have provided revenue estimates for PLX’s current fiscal year. The highest revenue estimate was $60.71M, while the lowest revenue estimate was $55.1M, resulting in an average revenue estimate of $57.91M. In the same quarter a year ago, actual revenue was $53.4MBased on 2 analysts’ estimates, the company’s revenue will be $106.2M in the next fiscal year. The high estimate is $119.46M and the low estimate is $92.94M.
